LUNAPHORE
28.3.2023 17:01:33 CEST | Business Wire | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the launch of a full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research. This milestone marks the launch of the enhanced version of the company’s revolutionary COMET™ platform and its comprehensive product suite, which includes a wide range of tools and applications across all research and drug development stages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005685/en/
Lunaphore's universal, end-to-end spatial biology solution portfolio. (Photo: Lunaphore)
Lunaphore’s multiplex immunofluorescence (mIF) solution portfolio now includes the latest version of the hyperplex, high-throughput, fully automated COMET™ instrument, providing unmatched scalability and reproducibility without the need to conjugate primary antibodies. The new SPYRE™ Antibody Panel kits, Secondary Antibodies, and an online Panel Builder have been added to the existing offering to help kick-start assay development and enable users with verified biomarkers on COMET™.
The product suite is further complemented by HORIZON™, an image analysis software designed and tailored for COMET™ hyperplex images. The software is developed by biologists for biologists to support them in answering fundamental questions about cell profiling and tissue mapping. With Lunaphore’s universal portfolio of precision automation solutions, customers can leverage their existing antibody libraries and decades of know-how on Lunaphore’s platform to scale assays into endless multiplexing possibilities.
“The spatial biology field is at an inflection point, and Lunaphore is at the forefront of this movement with its radically differentiated technological approach. Since the release of the first COMET™ platform a year ago, we so far observed high customer satisfaction and unmatched traction,” said Ata Tuna Ciftlik, CEO at Lunaphore. “We are really excited to launch our comprehensive future-ready solutions. This new COMET™ product suite embeds more than ten years of cutting-edge innovation into powerful tools that accompany our customers, from instant assay creation to streamlined research and analytics. We believe that the COMET ™ product suite is a cornerstone solution that will make spatial biology an everyday tool in laboratories around the globe.”
“A lot of work in our unit is around preclinical and trial work. We immediately recognized COMET™ as the top platform we were after,” said Dr. Andrew Filer, Head of the Birmingham Tissue Analytics Facility at the University of Birmingham. “We wanted a very high plex, fast, and robust instrument. All of the other platforms that were just coming into the market would have one major failure. The reason we liked COMET™ is that it doesn’t have any significant weaknesses. It covers all the bases, which is really important to us.”
Lunaphore’s complete product portfolio will be showcased at the American Association for Cancer Research (AACR) 2023 Annual Meeting through a series of activities and at the Lunaphore booth (#1870). To book a meeting or find out more about Lunaphore’s presence at the conference, please visit Lunaphore’s website.
To learn more about the new products in Lunaphore’s universal, end-to-end solution or start placing requests, please get in touch with the team at: info@lunaphore.com
To learn more about Lunaphore, please visit: https://lunaphore.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About HORIZON™
HORIZON™ is a tissue analysis software designed to simplify image analysis and evaluation. Tailored to COMET™ hyperplex immunofluorescence images, HORIZON™ extends the COMET™ workflow, providing a seamless integration between both systems, from a hyperplex image to cell phenotyping. HORIZON™ leverages COMET™-generated images and associated protocol information instantaneously. It can support assay development on COMET™, as well as image analysis workflows, by rapidly obtaining precise single-cell data for custom downstream analysis. HORIZON™ can perform cell segmentation in a few clicks thanks to a COMET™-specific, pre-trained algorithm, and the user-friendly and intuitive interface enables hyperplex analysis with no coding experience. With HORIZON™, it is possible to take full control of hyperplex data, visualizing all image channels with full flexibility and accurately finetuning histograms to see the adjustments applied instantly. The pre-release of HORIZON™ is now available for COMET™ users. To learn more about the HORIZON™ software, please visit: https://lunaphore.com/products/horizon/
About SPYRE™ Antibody Panel kits
The four SPYRE™ Antibody Panel kits - Immuno-Oncology, Immune, TIL, and T cell Core Panel – lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The assays developed with these kits can be modified or expanded with additional off-the-shelf antibodies from the customer’s own library to build custom panels for specific research needs without complexity. The primary antibody offering also includes Panel Builder, an online application providing exclusive access to a library of more than 70 successfully tested off-the-shelf markers and over 300 protocols. It provides an intuitive and convenient way to combine antibodies with SPYRE™ Antibody Panels to create panel protocols in silico, allowing ready-to-use COMET™ hyperplex protocols to be automatically generated in a few clicks. Orders of SPYRE™ Antibody Panel kits can be placed and will be available for shipment by the summer. To learn more about SPYRE™ Antibody Panels, please visit: https://lunaphore.com/spyre-antibody-panels/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom